18 Jul Touchlight
Jill Makin, Ph.D., Chief Scientific Officer
Oct. 6 | 5:00pm | FLW Ballroom F
Hampton, UK
(Private)
Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced dbDNA™ (doggybone DNA) to enable the development of genetic medicines and the first synthetic DNA technology to receive a GMP certificate globally. Touchlight provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licensing and tech transfer for use in-house.
